First CAR T-Cell trial launches for MS patients
NCT ID NCT07008378
Summary
This early-stage study is testing a new type of immune cell therapy called P-CD19CD20-ALLO1 in people with multiple sclerosis. The main goal is to check if the treatment is safe and how the modified cells behave in the body. Researchers will enroll 60 adults with either progressive or relapsing forms of MS to monitor side effects and track immune system changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110-1010, United States
Conditions
Explore the condition pages connected to this study.